Feature | September 17, 2014

Vascular Closure Devices Show Safety Comparable to Manual Compression

Results of ISAR-CLOSURE trial reported at TCT 2014

September 17, 2014 — A new clinical trial found that vascular closure devices (VCDs) are non-inferior to manual compression in patients undergoing transfemoral coronary angiography. The findings were reported at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) annual scientific sessions in Washington, D.C.

VCDs help achieve more rapid hemostasis after coronary angiography; however the safety and efficacy of these devices compared to standard manual compression remains controversial. Some meta-analyses have suggested an increased risk of vascular complications with VCD compared with manual compression, while other studies have demonstrated a reduction in bleeding complications with VCD.

The ISAR-CLOSURE trial compared outcomes after arteriotomy closure with two different VCDs to manual compression after diagnostic angiography performed through the femoral access route. The multicenter, open-label clinical trial randomized 4,524 patients undergoing diagnostic coronary angiography via the common femoral artery to receive either manual compression (n=1,509) or one of two VCDs (Femoseal VCD n=1,509; Exoseal VCD n= 1,506).

The primary endpoint was vascular access site complications, including the composite of hematoma greater than or equal to 5 centimeters, arterio-venous fistula, pseudoaneurysm, access-site related bleeding, acute ipsilateral leg ischemia, the need for vascular surgical or interventional treatment and local infection at 30 days after randomization. Secondary endpoints included time to hemostasis, repeat manual compression and device failure. A secondary comparison between the two VCDs was also performed.

After 30 days the VCD group reported access site complications in 6.9 percent of patients compared to 7.9 percent in the manual compression group, establishing non-inferiority of VCD. The most common complication in both groups was hematoma formation, followed by pseudoaneurym formation. Time to hemostasis was shorter in the VCD group (median 1 minute [.5-2.0] vs. 10 minutes [10-15], p<0.001), while the VCD group had a higher rate of repeat manual compressions (1.8 percent vs. 0.7 percent, p=0.003).

The secondary comparison found that the intravascular Femoseal VCD was associated with a tendency towards less vascular access-site complications as compared to the extravascular Exoseal VCD (6.0 percent versus 7.8 percent, p=0.043). (Due to multiple comparisons, a p-value of 0.025 was considered statistically significant.) In addition, time to hemostasis was shorter and device deployment failures were less frequent with the Femoseal VCD compared to the Exoseal VCD.

“In patients undergoing transfemoral coronary angiography, VCDs are non-inferior to manual compression in terms of vascular access site complications and reduced time to hemostasis,” said lead investigator Stefanie Schulz, M.D., from Deutsches Herzzentrum München in Germany. “The increase in efficacy of VCD with no trade-off in safety provides a sound rationale for the use of VCD over manual compression in daily routine.”

The ISAR-CLOSURE trial received no extramural funding. Schulz reported no disclosures.

For more information: www.crf.org, www.tctconference.com

Related Vascular Closure Content

Devices to Aid Hemostasis Speed Ambulation, Reduce Staff Time

Justifying the Use of Vascular Closure Devices

Vascular Closure Devices Show Safety Comparable to Manual Compression

Comparison Chart of Vascular Closure Devices

Related Content

Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
TherOx Gains FDA PMA Approval for SSO2 Therapy System
Technology | Cath Lab| September 29, 2017
September 29, 2017 — TherOx Inc. announced that the U.S.
Avinger Receives CE Mark for In-Stent Restenosis Indication With Pantheris Image-Guided Atherectomy
Technology | Atherectomy Devices| September 29, 2017
Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the...
Overlay Init